ClinicalTrials.gg
CompletedNCT03446846Updated Dec 17, 2020Results posted

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

A Phase 2 interventional study of MIN-117 5.0 mg and MIN-117 2.5 mg in Major Depressive Disorder, sponsored by Minerva Neurosciences. Completed at 47 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Minerva Neurosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Depressive Disorder, Major with a site in Ukraine — none open to participants now, none under way, none of them phase 3. Depressive Disorder, Major · Ukraine.

Enrollment
23rd of 36
360 · median 580
Started
2018
with 2 others
Phase 2
12 of 36
none open now
Registered
26th of 36
by date

Among the 36 studies in Depressive Disorder, Major with a site in Ukraine, this one is the 23rd largest by enrollment, is one of 3 that started in 2018, is one of 12 in phase 2, and was the 26th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 36 studies in Depressive Disorder, Major with a site in Ukraine is open now. The open studies under Depressive Disorder, Major, anywhere →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Depressive Disorder, Major with a site in Ukraine as a file.
02

Study summary

MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years. Approximately 324 patients were to be randomly assigned to 1 of 3 treatment arms, including placebo, 2.5 mg MIN-117, or 5.0 mg MIN-117, in a 2:1:1 ratio.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • MIN-117
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to read and understand the consent forms, complete study-related procedures, and communicate with the study staff.
  • Participants must have provided written consent to participate in the study and understand that they are free to withdraw from the study at any time.
  • Participants must have signed the form for pharmacogenomic research indicating willingness to participate in the pharmacogenomic component of the study in order to participate in the optional pharmacogenomic component of this study. Refusal to consent for this component does not exclude a participant from participation in the clinical study.
  • Participants must be aged 18 to 65 years, inclusive, at Screening (Visit 1).
  • Meet 5th edition (DSM-5) criteria for diagnosis of moderate or severe major depression with anxious distress and without psychotic features at Screening based on clinical assessment and on the Structured Clinical Interview for DSM-5 (SCID-5). Their major depressive episode must be deemed "valid" using the Massachusetts General Hospital (MGH) State versus trait; Assessability; Face validity; Ecological validity; and Rule of three Ps [pervasive, persistent, and pathological] (SAFER) criteria interview administered by remote, independent raters.
  • Participants must be within a (BMI) of ≥ 18 to \< 35 kg/m2 (BMI = weight (kg)/height(m)2] at Screening (Visit 1).
  • Participants have a history of at least one previous episode of depression prior to the current episode.
  • Participant must have been treated with an antidepressant administered at an adequate dose and duration in the past for the treatment of Major Depression. An adequate treatment is defined as an antidepressant treatment for at least 4 weeks at at least the minimum therapeutic dose, for any particular antidepressant.
  • Current major depressive episode of at least 4 weeks in duration.
  • At Screening (Visit 1) and Baseline (Visit 2), participants must have a score ≥ 40 on the patient rated Inventory of Depressive Symptoms self-report (IDS-SR30).
  • At Screening (Visit 1) and Baseline (Visit 2), participants must have a score ≥ 18 on Hamilton Anxiety Scale (HAM-A).
  • At Screening (Visit 1) and Baseline (Visit 2), participants must have a score ≥ 4 on the investigator-rated Clinical Global Impression of Severity Scale (CGI-S).
  • Participants must be outpatients at the time of randomization (Baseline [Day 1]).
  • Participants must be in good general health prior to study participation with no abnormalities as assessed by the investigator and determined by: medical history, physical examination, vital signs, blood chemistry, hematology, urinalysis, and (ECG).
  • If female, the participant must:

    1. be , or
    2. have had a hysterectomy or tubal ligation or be otherwise incapable of pregnancy, or
    3. must agree to consistent use of 2 methods of for the duration of the study and until 90 days after the last dose of study medication.
  • Female participants of must have a negative serum pregnancy test at Screening (Visit 1) and negative serum and urine pregnancy test at Baseline (Visit 2).

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of current (active): panic disorder, obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), anorexia nervosa, or bulimia nervosa.
  • History or current diagnosis of a psychotic disorder, bipolar disorder, mental retardation, or borderline personality disorders, mood disorder with postpartum onset, somatoform disorders, fibromyalgia, or idiopathic medical conditions.
  • At significant clinical risk for suicidal or violent behavior.
  • History of treatment within last 6 months with electroconvulsive therapy (ECT), Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), or Transcranial Magnetic Stimulation (TMS).
  • Potential participant who in the opinion of the investigator should not discontinue, or participate in washout of a prohibited concomitant medication.
  • Potential participant who demonstrates a greater than 25% decrease in depressive symptoms as reflected by the IDS-SR30 total score from Screening visit to Baseline visit.
  • Active cardiovascular disease (including but not limited to: atrial fibrillation or flutter, second and third-degree atrioventricular heart block, resting supraventricular tachycardia > 100 beats per minute, unstable ischemic heart disease, valvular abnormality, sick sinus syndrome or other condition requiring pacemaker) or diastolic blood pressure > 105 mmHg.
  • Any serious, untreated, or unstable illnesses, such as: liver or renal insufficiency.
  • Any significant pulmonary, endocrine, or metabolic disturbances.
  • Documented disease of the central nervous system that could interfere with the study assessments (including by not limited to: stroke, tumor, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, seizure disorder requiring current anti-convulsants, traumatic brain injury or trauma, and neurosyphilis.
  • Hypothyroidism or hyperthyroidism, unless stabilized by appropriate medication for at least 3 months prior to Screening (a normal thyroid-stimulating hormone [TSH] is required prior to randomization at Baseline).
  • Any medical condition that can potentially alter oral enteral absorption (e.g., gastrectomy), metabolism (e.g., liver failure), or excretion (e.g., renal failure) of the study drug.
  • History of alcohol or substance use disorders (except nicotine and caffeine) meeting DSM-5 criteria within 1-year prior to Screening visit.
  • Positive alcohol and urine drug screen for opiates, cocaine, barbiturates, tetrahydrocannabinol, methadone, tricyclic antidepressants, benzodiazepines, and amphetamine/methamphetamine at Screening or Baseline. Patients with positive testing at Screening due to prescribed benzodiazepines, tricyclic antidepressants, barbiturates or opiates are accepted but must test negative at Baseline.
  • Male participants who have pregnant partners.
  • Received an experimental drug or used an experimental medical device within 60 days before the planned start of treatment (Day 1) or have participated in 2 or more clinical trials in the previous 2 years.
  • corrected with Fridericia's formula (QTcF) at Screening or Baseline greater than 450 msec for males and 470 msec for females.
  • Positive surface antigen, or antibody or (HIV) 1 and 2 antibodies at Screening.
  • Employees of the investigator or study center, when the employee has direct involvement in the proposed study or other studies under the direction of that investigator or study center; also family members of the employee or the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    5.0 mg MIN-117

    MIN-117 5.0 mg (consisting of two 2.5 mg capsules) orally daily for 6 weeks

    Drug: MIN-117 5.0 mg

  • Experimental
    2.5 mg MIN-117

    MIN-117 2.5 mg (consisting of one 2.5 mg capsule and one placebo capsule) orally daily for 6 weeks

    Drug: MIN-117 2.5 mg

  • Placebo comparator
    Placebo

    Placebo (consisting of two placebo capsules) orally daily for 6 weeks

    Drug: Placebo

Interventions

  • DrugMIN-117 5.0 mg

    5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily

  • DrugMIN-117 2.5 mg

    2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily

  • DrugPlacebo

    Placebo administered as two Placebo capsules as a single dose once daily

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The Montgomery-Asberg Depression Rating Scale (MADRS) is a validated, physician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe conditions. MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The test exhibits high inter-rater reliability and its capacity to differentiate between responders and nonresponders to antidepressant treatment has been shown to be comparable to the Hamilton Rating Scale for Depression.

    Time frame: Week 6

Secondary outcomes

  1. Change in Hamilton Anxiety Scale (HAM-A)

    Hamilton Anxiety Scale (HAM-A) measures the severity of a participant's anxiety, based on 14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and behavior at the interview. The subject is asked to rate the gravity of each item using a 5-level scale - from 0 to 4, where 0 being not present and 4 being severe - and afterwards, the results are collated and tabulated to determine the severity of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-25 mild to moderate severity, 25-30 moderate to severe, and \>30 indicates very severe. To implement the HAM-A, the acting clinician proceeds through the 14 items, evaluating each criterion independently in form of the five-point scale described above.

    Time frame: Change from Baseline to the end of Week 6

  2. Change in Clinical Global Impression of Severity Scale (CGI-S)

    The Clinical Global Impression of Severity (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" which is rated on the following scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. The CGI-S will provide an overall clinician-determined summary measure that takes into account all available information including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function.

    Time frame: Change from Baseline to Week 6

  3. Change in Clinical Global Impression of Improvement Scale (CGI-I) at Week 6

    The Clinical Global Impression of Improvement Scale (CGI-I) will provide an overall clinician-determined summary measure that takes into account all available information including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-I consists of a 7-point scale that evaluates the change from initiation of treatment similar to the Clinical Global Impression of Severity Scale (CGI-S). This 7-point scale requires the clinician to assess how much the subject's illness has improved or worsened relative to a Baseline state at the beginning of the intervention and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

    Time frame: Week 6

07

Results

Posted Dec 17, 2020
Limitations and caveats
No notable study limitations were identified.

Participant flow

Participant flow — Overall Study
Milestone5.0 mg MIN-1172.5 mg MIN-117Placebo
Started9092178
Completed8387162
Not completed7516

Outcome measures

PrimaryChange in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The Montgomery-Asberg Depression Rating Scale (MADRS) is a validated, physician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe conditions. MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The test exhibits high inter-rater reliability and its capacity to differentiate between responders and nonresponders to antidepressant treatment has been shown to be comparable to the Hamilton Rating Scale for Depression.

Time frame:
Week 6
Reported as:
Mean · score on a scale
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scale5.0 mg MIN-1172.5 mg MIN-117Placebo
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-12 ± 9.2-12 ± 9.2-12 ± 9.2
SecondaryChange in Hamilton Anxiety Scale (HAM-A)

Hamilton Anxiety Scale (HAM-A) measures the severity of a participant's anxiety, based on 14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and behavior at the interview. The subject is asked to rate the gravity of each item using a 5-level scale - from 0 to 4, where 0 being not present and 4 being severe - and afterwards, the results are collated and tabulated to determine the severity of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-25 mild to moderate severity, 25-30 moderate to severe, and \>30 indicates very severe. To implement the HAM-A, the acting clinician proceeds through the 14 items, evaluating each criterion independently in form of the five-point scale described above.

Time frame:
Change from Baseline to the end of Week 6
Reported as:
Mean · score on a scale
Change in Hamilton Anxiety Scale (HAM-A)
score on a scale5.0 mg MIN-1172.5 mg MIN-117Placebo
Change in Hamilton Anxiety Scale (HAM-A)-12 ± 8.0-11 ± 9.1-11 ± 8.5
SecondaryChange in Clinical Global Impression of Severity Scale (CGI-S)

The Clinical Global Impression of Severity (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" which is rated on the following scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. The CGI-S will provide an overall clinician-determined summary measure that takes into account all available information including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function.

Time frame:
Change from Baseline to Week 6
Reported as:
Mean · score on a scale
Change in Clinical Global Impression of Severity Scale (CGI-S)
score on a scale5.0 mg MIN-1172.5 mg MIN-117Placebo
Change in Clinical Global Impression of Severity Scale (CGI-S)-1 ± 1.3-1 ± 1.1-1 ± 1.2
SecondaryChange in Clinical Global Impression of Improvement Scale (CGI-I) at Week 6

The Clinical Global Impression of Improvement Scale (CGI-I) will provide an overall clinician-determined summary measure that takes into account all available information including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-I consists of a 7-point scale that evaluates the change from initiation of treatment similar to the Clinical Global Impression of Severity Scale (CGI-S). This 7-point scale requires the clinician to assess how much the subject's illness has improved or worsened relative to a Baseline state at the beginning of the intervention and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

Time frame:
Week 6
Reported as:
Mean · score on a scale
Change in Clinical Global Impression of Improvement Scale (CGI-I) at Week 6
score on a scale5.0 mg MIN-1172.5 mg MIN-117Placebo
Change in Clinical Global Impression of Improvement Scale (CGI-I) at Week 63 ± 1.03 ± 1.23 ± 1.1

Adverse events

Collected over Approximately up to 11 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5.0 mg MIN-1170/91 (0%)0/91 (0%)11/91 (12.1%)
2.5 mg MIN-1170/92 (0%)1/92 (1.1%)11/92 (12%)
Placebo0/177 (0%)0/177 (0%)13/177 (7.3%)
Most frequent serious events
Most frequent serious events
Event5.0 mg MIN-1172.5 mg MIN-117Placebo
Feeling guiltyPsychiatric disorders0/911/920/177
Major depressionPsychiatric disorders0/911/920/177
Suicidal ideationPsychiatric disorders0/911/920/177
Most frequent other events
Most frequent other events
Event5.0 mg MIN-1172.5 mg MIN-117Placebo
HeadacheNervous system disorders11/9111/9213/177

Baseline characteristics

One patient was randomized to a particular kit # in the Electronic Data Capture system, however, the site dispensed another kit # instead in error. Consequently, the patient was randomized to placebo but received 5.0 mg MIN-117 and was, therefore, included in the (Intent-to-Treat) ITT population based on the randomized treatment to placebo and in the safety population based on the actual treatment they received (5.0 mg MIN-117).

Age, Categorical
Age, Categorical(Participants)5.0 mg MIN-1172.5 mg MIN-117PlaceboTotal
<=18 years0000
Between 18 and 65 years9192177360
>=65 years0000
Age, Continuous
Age, Continuous(years)5.0 mg MIN-1172.5 mg MIN-117PlaceboTotal
Mean48 ± 11.547 ± 12.747 ± 12.548 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)5.0 mg MIN-1172.5 mg MIN-117PlaceboTotal
Female6260136258
Male293241102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5.0 mg MIN-1172.5 mg MIN-117PlaceboTotal
American Indian or Alaska Native0000
Asian1113
Native Hawaiian or Other Pacific Islander0000
Black or African American541120
White8587165337
More than one race0000
Unknown or Not Reported0000
08

Study locations

47 sites
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845, United States
  • Collaborative Neuroscience Network, LLC
    Torrance, California 90502, United States
  • Pacific Clinical Research Medical Group
    Upland, California 91786, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Hassman Research Institute, LLC
    Berlin, New Jersey 08009, United States
  • Neurobehavioral Research, Inc, Cedarhurst, NY
    Cedarhurst, New York 11516, United States
  • Neuro-Behavorial Clinical Research Inc
    Canton, Ohio 44718, United States
  • Oregon Center for Clinical Investigations
    Portland, Oregon 97214, United States
  • FutureSearch Trials
    Dallas, Texas 75231, United States
  • Mental Health Centre "Prof. Dr. Ivan-Temkov - Burgas" EOOD Complex Lazur
    Burgas, Bulgaria
  • "University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski" EAD, First psychiatric clinic
    Pleven, Bulgaria
  • UMHAT "Sveti Georgi" EAD - Psychiatry Clinic
    Plovdiv, Bulgaria
  • Mental Health Center, Ruse
    Ruse, Bulgaria
  • "Diagnostic-Consultative Center St. Vrach and St. St. Kuzma and Damyan" OOD, Psychiatric office
    Sofia, Bulgaria
  • "Medical Center Stimul" OOD, Psychiatric office
    Sofia, Bulgaria
  • MC Intermedika
    Sofia, Bulgaria
  • MC Sveti Naum, Sofia
    Sofia, Bulgaria
  • DCC Mladost-M OOD
    Varna, Bulgaria
  • Helsingin Psykiatripalvelu Oy at Mehilainen Clinic, Lääkärikeskus Mehiläinen
    Helsinki, Finland
  • Oulu Mentalcare Oy
    Oulu, Finland
  • Satakunnan Psykiatripalvelu Oy at Mehiläinen Pori
    Pori, Finland
  • Mentoria
    Tampere, Finland
  • Center for Mental Health and Prevention of Addiction Ltd
    Tbilisi, Georgia
  • Tbilisi Mental Health Center Ltd
    Tbilisi, Georgia
  • Department of Psychiatry, Addiction and Medical Psychology
    Chisinau, Moldova, Republic of
  • Podlaskie Centrum Psychogeriatrii
    Białystok, Poland
  • Ośrodek Badań Klinicznych - Clinsante S.C.
    Bydgoszcz, Poland
  • Zespół Opieki Zdrowotnej w Chełmnie, Poradnia Zdrowia Psychicznego
    Chełmno, Poland
  • ISPL
    Gdańsk, Poland
  • NZOZ Syntonia
    Pruszcz Gdański, Poland
  • Prywatna Klinika Psychiatryczna Inventiva
    Tuszyn, Poland
  • Communal Institution "Dnipropetrovsk Regional Clinical Hospital n.a. I.I.Mechnykov", Regional Center of Psychosomatic Disorders based on Psychoneurology
    Dnipro, Ukraine
  • Municipal non-Profit enterprise "Carpathian Regional Mental
    Ivano-Frankivsk, Ukraine
  • State Institution "Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine" Department of Neuroses and Borderline States
    Kharkiv, Ukraine
  • The Training and Research Medical Complex "The Clinic" otharkiv National Medical University
    Kharkiv, Ukraine
  • Municipal non-profit enterprise "Kherson Regional Psychiatric Care Facility"
    Kherson, Ukraine
  • Municipal Non-Profit Enterprise "Kirovohrad Regional Psychoneurological Hospital of Kirovohrad Regional Council
    Kropyvnytskyi, Ukraine
  • Municipal enterprise "Heikiv Psychoneurological Hospital, Dnipropetrovsk Regional Council"
    Kryvyy Rih, Ukraine
  • Kyiv Clinical Hospital on Railway Transport #1 of the branch "Health Center" of the joint-stock company "Ukrainian Railway"
    Kyiv, Ukraine
  • Kyiv Regional Medical Incorporation Psychiatry Center of Novel Treatment and Rehabilitation of Psychotic Disorders
    Kyiv, Ukraine
  • Municipal Institution of Kyiv Regional Council "Regional Psychiatric and Narcological Medical Association"
    Kyiv, Ukraine
  • National Military-Medical Clinical Center Main Military
    Kyiv, Ukraine
  • Municipal non-profit enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital"
    Lviv, Ukraine
  • Municipal Non-Profit Enterprise "Odessa Regional Psychiatric Hospital # 2" "of Odessa Regional Council"
    Odessa, Ukraine
  • Communal enterprise "Poltava Regional Clinical Psychiatric Hospital named O.F. Maltsev Poltava Regional Council"
    Poltava, Ukraine
  • Municipal non-profit enterprise"Vinnytsya Regional Psychoneurological Hospital named Acad. O.I. Yushchenko of Vinnytsya Regional Council
    Vinnytsya, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Nov 2019, 19 months.

Results were first posted in Dec 2020, 1 year after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 19 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2018
First posted
Feb 27, 2018
StartActual
Mar 30, 2018
Primary completionActual
Nov 21, 2019
CompletionActual
Dec 13, 2019
Results first posted
Dec 17, 2020
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03446846
Lead sponsor
Minerva Neurosciences
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Mar 30, 2018
Primary completion
Nov 21, 2019
Completion
Dec 13, 2019
Results posted
Dec 17, 2020
Last update
Dec 17, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion